ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2892

Masp-1/3 Deficient MRL/Lpr Mice Lack The Alternative Complement Pathway Activation and Are Protected From Development Of Lupus-Like Glomerulonephritis

Takeshi Machida1, Natsumi Sakamoto1, Teizo Fujita1, Minoru Takahashi2 and Hideharu Sekine1, 1Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, complement, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Complement has both protective and pathogenic functions in lupus due to a balance between its role in the clearance of immune complexes (ICs) and apoptotic cells and its role in inflammation. The classical pathway is thought to contribute to IC and apoptotic cell clearance, whereas the alternative pathway is a key mediator of renal inflammation. Mannose-binding lectin (MBL)-associated serine proteases (MASPs)-1 and -3 are responsible for activation of the alternative pathway by activation of complement factor D which is required to cleave C3b-bound factor B to Bb (the C3 convertase (C3bBb)) during the alternative pathway activation. The aim of this study was to investigate the role of essential components of the alternative pathway, MASP-1/3, on lupus-like renal disease in MRL/lpr mice.

Methods: MASP-1/3 gene-knockout MRL/lpr mice were generated by backcrossing MASP-1/3-/-C57BL/6 mice for seven generations to MRL/lpr mice, a mouse strain that spontaneously develops lupus-like disease. Alternative pathway activity in serum was measured by zymosan assay. Sera were analyzed every 2 weeks for total IgG, IgG anti-dsDNA autoantibodies, and C3 levels by ELISA. Urinary excretion of albumin was also determined. Kidneys were collected at 24 weeks for histologic evaluation.

Results: Sera from WT MRL/lpr mice showed significant C3 deposition on zymosan particles, whereas sera from MASP-1/3-/- MRL/lpr mice failed.  Interestingly, compared to WT MRL/lpr mice, MASP-1/3-/- MRL/lpr mice had significantly increased levels of serum total IgG. However, there was no statistically significant difference of serum IgG anti-dsDNA antibody levels between the two groups. Serum C3 levels in WT MRL/lpr mice decreased as the mice aged. In contrast, serum C3 levels in MASP-1/3-/-mice were maintained, and were significantly higher than those in the WT group at and after week 16. There was no significant difference in glomerular IgG deposition levels between WT and MASP-1/3-/- groups. Importantly, minimal or no glomerular C3 deposition was observed in MASP-1/3-/- MRL/lpr mice, while it was ready evident in WT MRL/lpr mice. Unlike WT MRL/lpr mice, none of MASP-1/3-/- MRL/lpr mice developed albuminuria (no more than 100 micro-g/day/mouse) until 24 weeks of age. Pathological analysis revealed minimal or no glomerular disease in MASP-1/3-/- MRL/lpr mice; however, there was no significant reduction in interstitial nephritis compared to WT MRL/lpr mice.

Conclusion: Unlike WT MRL/lpr mice, MASP-1/3-/- MRL/lpr mice lacked activity of the alternative pathway, and had maintained serum C3 levels, no albuminuria, and minimal or no glomerular C3 deposition and glomerular pathologic changes. Thus, inhibition of the alternative pathway protects against the development of glomerular disease in lupus-prone MRL/lpr mice. MASP-1/3-/- MRL/lpr mice, however, had no significant reduction in interstitial nephritis, suggesting that the pathological mechanism of interstitial kidney disease was distinct from that of glomerular disease in MRL/lpr mice.


Disclosure:

T. Machida,
None;

N. Sakamoto,
None;

T. Fujita,
None;

M. Takahashi,
None;

H. Sekine,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/masp-13-deficient-mrllpr-mice-lack-the-alternative-complement-pathway-activation-and-are-protected-from-development-of-lupus-like-glomerulonephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology